Home | Welcome to Contract Pharma   
Last Updated Saturday, May 25 2013
Print RSS Feed

Breaking News

Related Searches: Collaborations & Alliances •
Alnylam, Takeda in RNAi Pact

May 27, 2008
Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This collaboratio…  Read More »
WuXi PharmaTech

May 27, 2008
WuXi PharmaTech has named Dr. Peng Wang to the role of vice president of Discovery Biology. Dr. Wang will oversee the company's growing portfolio of discovery biology service offerings. He will report directly to Dr. Ge Li, the company's chairman and…  Read More »
Takeda San Francisco

May 23, 2008
Mary Haak-Frendscho, Ph.D. has been appointed president and chief scientific officer, Takeda San Francisco, Inc. Dr. Haak-Frendscho will be responsible for leading all activities at the company, including overall research and preclinical development,…  Read More »
Microfluidics

May 23, 2008
William J. Conroy has been appointed vice president of operations and engineering at Microfluidics, a wholly owned subsidiary of MFIC Corp. In this position, Mr. Conroy will have P/L responsibility for the operating division of both Microfluidics and…  Read More »
DOR BioPharma Opens UK Office

May 23, 2008
DOR BioPharma has opened a new corporate office in the UK. The new office gives DOR a presence in the EU to better facilitate the Named Patient Access program that will be administered by IDIS, also based in the UK. Serving as the company's official…  Read More »
Norwich Pharmaceuticals

May 22, 2008
Norwich Pharmaceuticals, Inc. has made several appointments as part of the company's initiative to expand its contract manufacturing and packaging services. Douglas L. Drysdale has been appointed to the newly created position of chief executive offic…  Read More »
Eli Lilly and Co.

May 22, 2008
Eli Lilly and Co. has made changes across its executive leadership structure. "Earlier this year I asked each of our senior leaders to look closely at their respective areas to determine if they were optimally structured to meet the demands of o…  Read More »
BioScreen Testing Services, Inc.

May 22, 2008
Orly Zargar has been appointed the West Coast business development representative for Personal Care, BioScreen Testing Services, Inc. Ms. Zargar is responsible for supporting and contributing to the company's continued growth.    …  Read More »
Daiichi Sankyo To Acquire U3 Pharma

May 21, 2008
Daiichi Sankyo Co., Ltd. has entered into an agreement to acquire U3 Pharma AG, a privately held German biotechnology company focusing on antibody research for the treatment of cancer. Daiichi Sankyo will purchase all of the stock and make a one-time…  Read More »
Almac Adds Record Number of New Studies

May 21, 2008
Almac Clinical Technologies, a division of the Almac Group, has signed a record $12 million worth of new studies within the past several weeks, including a global mega-study involving almost 20,000 patients.     Almac Clinical Techn…  Read More »
Sanofi-aventis, Regeneron Update Cancer Program

May 21, 2008
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. have updated the clinical development program for aflibercept, and provided results from a Phase II study in advanced ovarian cancer. The companies reported that a recent study did not achieve its pr…  Read More »
Oso Buys Injectables Unit from Catalent

May 20, 2008
Oso Biopharmaceuticals Manufacturing, LLC has purchased the Albuquerque, NM-based sterile injectables manufacturing business of Catalent Pharma Solutions. Terms of the transaction were not disclosed.     The unit provides cGMP glass…  Read More »
MDS Pharma Services

May 20, 2008
Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named executive medical directors for respiratory disorders and metabolic disorders, respectively, MDS Pharma Services.     "Pharmaceutical companies are pursuing clinica…  Read More »
KAI Pharma Advances Candidate into Clinic

May 20, 2008
KAI Pharmaceuticals has initiated enrollment in a Phase I study of KAI-1678, a first-in-class, isozyme-selective inhibitor of the epsilon protein kinase C pathway. KAI-1678 has been shown to be highly effective at reducing pain responses in a wide va…  Read More »
Schering-Plough, MorphoSys Extend Antibody Alliance

May 19, 2008
Schering-Plough Corp. has extended its collaboration with MorphoSys AG for one year. The collaboration, announced in May 2006, has a maximum term of five years until 2011 and may be extended by SP after each year. Under the agreement, SP will continu…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: